Patent issues still trouble pharmaceutical companies

Regulatory uncertainty adds to sector’s difficulties, but managers find directional trades

The performance of major pharmaceutical companies has been severely hampered over the last year by patents ending and the continuing absence of a president for America’s Food and Drug Administration (FDA).

Large pharmaceutical firms have begun to perform better with the appointment of Mark McClellan as FDA commissioner last November, but firms’ patent problems persist. They do, however, bring with them opportunities for smaller pharmaceutical companies in emerging markets, according to specialist

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@risk.net or view our subscription options here: http://subscriptions.risk.net/subscribe

You are currently unable to copy this content. Please contact info@risk.net to find out more.

Sorry, our subscription options are not loading right now

Please try again later. Get in touch with our customer services team if this issue persists.

New to Risk.net? View our subscription options

Most read articles loading...

You need to sign in to use this feature. If you don’t have a Risk.net account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here